A year later, most of them were still better
What they did
Researchers followed twenty-four adults from the earlier Johns Hopkins depression trial for a full year after their second psilocybin dose.
What they found
Improvements held. Seventy-five percent still showed at least a 50 percent reduction in symptoms at twelve months and 58 percent were in remission, with no serious side effects linked to psilocybin during follow-up.
Worth knowing
This follows people from an uncontrolled waiting-list study, so there is no comparison group to say what would have happened anyway. Twenty-four people is small for a durability claim.
Gukasyan et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder, prospective 12-month follow-up. Journal of Psychopharmacology, 2022.
Read the sourceKeep reading
depressionOnly the highest dose eased treatment-resistant depressiondepressionIn ordinary depression, psilocybin beat placebo by twelve pointsdepressionPsilocybin and a standard antidepressant, with no clear winnerEvery trial in this section used a single large dose, given in a clinic, with trained people in the room for the whole session. That is a different activity from anything sold on this site. More on why that distinction matters.
For education, not medical advice. Every write-up links back to the original source.
Nothing here is a claim that our products treat, cure or prevent any condition. Talk to a doctor before changing anything about your health.